Ferrari Challenge UK continues at Brands Hatch with Yates leading

Benedetto Vigna Chief Executive Officer Ferrari N.V.
Benedetto Vigna Chief Executive Officer - Ferrari N.V.
0Comments

The Ferrari Challenge UK Trofeo Pirelli race series is set to continue this week at the Brands Hatch circuit in Kent. This marks the third race of the year for the series.

In the Trofeo Pirelli class, 2024 champion Gilbert Yates from Charles Hurst maintains his lead with 67 points. He holds a 14-point advantage over Pranav Vangala of HR Owen, following a double victory at Oulton Park in May. Calum Leathem, also from Charles Hurst, is third in the standings and has achieved two podium finishes in his debut season.

The Coppa Shell category sees a tight competition among leaders Mike Dewhirst of Dick Lovett Swindon, Paul Simmerson from Graypaul Birmingham, and Peter Hunter representing Stratstone Manchester. Dewhirst leads with 60 points, but only eight points separate him from Simmerson and Hunter who have 52 and 50 points respectively.

Further down the standings are Steven Dopson of Dick Lovett Swindon and Paul Rogers from HR Owen, both tied on 28 points and seeking their first podium finish this season.

Weather conditions are expected to be favorable for racing at Brands Hatch. Competitors will navigate the Indy layout on Saturday followed by the GP layout on Sunday.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.